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Many physical and chemical agents used in anti-neoplastic therapy are known to act by
effecting DNA damage. The possibility that calmodulin may be an important modulator of the
response to DNA damage in eukaryotic cells has been explored in a number ofstudies which use
calmodulin antagonists in combination with agents known to damage DNA. We review these
studies and discuss the therapeutic potential ofcalmodulin antagonists in combination therapy.
Many physical and chemical anti-neoplastic agents are known to produce their
therapeutic effects by damaging DNA. The potential to enhance therapeutic efficacy
bythepotentiation ofDNAdamage, eitherdirectly orvia theinhibition ofDNA repair
processes, suggests novel opportunities for thedevelopment ofanti-neoplastic regimens
in more effective treatment ofpatients with cancer. Recent research using calmodulin
antagonists has suggested that calmodulin may be important in thedamage and repair
of DNA. We reviewed the data examining the interactions ofcalmodulin antagonists
with agents known to induce DNA damage.
In recent years the existence ofa calcium messenger system as a fundamental means
ofregulating cellular functions has been well established. The large gradient between
extracellular Ca++ concentrations (1 mM) and intracellular free calcium concentra-
tion (100-200 nanomolar) is maintained by a complex series of homeostatic mecha-
nisms. Small changes in intracellular calcium concentrations affect a wide variety of
cellular functions as part of a "second messenger" system analogous to the cyclic
adenosine 3',5-monophosphate (cAMP) messenger system. A small calcium-binding
protein, calmodulin, plays an important role in the calcium messenger system [1,2].
Calmodulin was discovered in the late 1960s and has been reviewed extensively in
recent years [3,4,5,6,7,8,9]. It is a small (148 amino acid, molecular weight 16,700),
acidic (pl 3.9), heat-stable protein present in all eukaryotic cells examined to date. It
has been highly conserved across evolutionary lines, and only subtle differences have
been identified in the sequences ofcalmodulins purified from species which are widely
separated phylogenetically, a factor which implies that calmodulin is part of a
regulatory system common to all eukaryotic cells.
Each molecule of calmodulin has four structurally similar domains, each of which
can bind a single Ca++ ion in response to changes in the intracellular calcium
concentration (kd 3.5 x 10-6M). The binding of Ca++ to calmodulin produces
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conformational changes, which allow the specific interaction of calmodulin with a
number of target proteins. In this manner, activity of the target proteins is increased,
causing changes in a variety ofcellular functions.
Strict criteria for the designation ofcalmodulin-dependent processes have been set
forth by Cheung, one ofthe first to describe the protein [10]. Enzymes which have met
the stringent criteria include those involved in cyclic nucleotide metabolism [11],
protein phosphorylation [12], energy metabolism [13], and other key cellular func-
tions. The list of processes in which calmodulin has been implicated as a regulator is
much longer and includes such processes as DNA synthesis [14], cell growth and
differentiation [15], and microtubular function [16], which are important in consider-
ation ofthe role calmodulin may play in neoplastic cells.
A large number ofcompounds have been demonstrated to becalmodulin antagonists
(for reviews, see [17,18,19]. The phenothiazine familyofcompounds, used clinically as
anti-psychotics, were the first compounds to be used experimentally as calmodulin
inhibitors. A wide variety of compounds from different structural classes has subse-
quently been shown to have calmodulin antagonist activity, including the napthalene-
sulfonamide, or "W" compounds.
The large body of research that examines the role of calmodulin in neoplasia has
been discussed in several reviews [15,20,21,22]. Hait and Lazo have summarized a
large number of investigations in which calmodulin antagonists have been shown to
inhibit cell growth and produce cytotoxicity [22]. Most experiments have involved
work with malignant cell lines in culture, although some in vivo animal experiments
have been reported and clinical trials are currently in progress. Many of the studies
summarized demonstrated a good correlation between the concentration ofcalmodulin
inhibitors required to inhibit clonogenicity and the concentration required to inhibit
calmodulin in cell-free assay systems.
Several lines of research address the role that calmodulin may play in neoplastic
cells. Increased concentrations of calmodulin have been reported in some but not all
studies in which the calmodulin content of hyperproliferative and malignantly
transformed cells has been compared to that of controls [15]. Cell-cycle specific
elevations in calmodulin content have been reported, and progression through the cell
cycle has been shown to be inhibited by calmodulin antagonists [23,24]. The capacity
of calmodulin to alter protein activity by phosphorylation leaves open, however, the
possibility that calmodulin may specifically affect neoplastic cells via the regulation of
as yet unidentified processes. As mentioned previously, data implicate calmodulin as a
regulator of many more processes than are at present definitively categorized as
calmodulin-dependent.
The following review attempts to summarize the data linking calmodulin to the
fundamental cellular process of DNA repair. Experiments have been conducted using
physical factors known to induce DNA damage, such as ultraviolet (UV) light,
X-irradiation, and hyperthermia, in conjunction with calmodulin antagonists. In
addition, many chemotherapeutic agents currently in use are thought to exert their
therapeutic effects by inducing DNA damage, and experiments have been performed
which examine their interactions with calmodulin antagonists. The potentiation of
therapeutic effects produced by DNA damage in malignant cells may be mediated by
the inhibition ofDNA repair processes. Thus, thefindings that calmodulin antagonists
may be regulators of DNA repair indicate that there may be a role for calmodulin
antagonists as components ofnew regimens in anti-neoplastic therapy.
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CALMODULIN ANTAGONISTS AND BLEOMYCIN
Using Chinese hamster ovary (CHO) cells growing exponentially in culture,
Chafouleas, Bolton, and Means examined the effects of calmodulin inhibitors in
combination with bleomycin, an anti-tumor antibiotic thought to act by fragmenting
DNA [25]. The authors noted that when CHO cells were treated with non-toxic
concentrations of bleomycin in combination with non-toxic concentrations of W-13, a
napthalenesulfonamide calmodulin inhibitor, a dramatic decrease in the fraction of
surviving cells occurred. There was a dose-dependent decrease in the surviving fraction
of cells as the concentration of W-13 was increased. This effect was not noted when
compound W-12, an analog of W-13, which is not active as a calmodulin antagonist,
was used. The effect of this combination treatment was most prominent when cells
were first exposed to bleomycin, then allowed to recover from bleomycin-induced
lethal damage in the presence of the phenothiazine calmodulin inhibitor, trifluopera-
zine.
The authors postulated that their results were due to the inhibition ofa calmodulin-
dependent process of DNA repair. In support ofthis hypothesis, they found a decrease
in the nucleoid sedimentation migration rate, a measure shown to correlate with DNA
damage, in nucleoids which had been prepared from cells treated with bleomycin. In
cells treated with bleomycin and then allowed to recover in either fresh medium or
medium containing the inactive congener W-12, recovery of the nucleoid sedimenta-
tion migration rate was no different from that of controls. In cells treated with
bleomycin which were allowed to repair in medium containing the calmodulin inhibitor
W-13, however, the nucleoid sedimentation migration rate was approximately that of
the control cells treated with bleomycin alone, which were not given theopportunity for
repair. The authors concluded that DNA repair had not taken place in presence ofthe
calmodulin antagonist W-13 but had occurred in the presence of the inactive
compound, W-12.
In addition, Chafouleas and his colleagues found that W-13 did not potentiate DNA
damage induced by bleomycin in E. coli [25]. Unlike eukaryotes, E. coli and other
prokaryotes do not contain calmodulin. This system provided additional support for
their contention that the potentiation of bleomycin cytotoxicity by calmodulin antago-
nists was due to the inhibition ofcalmodulin.
Lazo, Hait, and their colleagues also reported the effects of calmodulin antagonists
in combination with bleomycin on the viability of malignant cells [26,27,28]. For
example, in L1210 murine leukemia cells, bleomycin cytotoxicity was enhanced by a
variety of different structural classes of calmodulin antagonists including the naptha-
lenesulfonamide, W-7, the phenothiazines, trifluoperazine and chlorpromazine, the
diphenylbutylpiperidine, pimozide, and the bee venom peptides, melittin and mastopo-
ran. The potentiation of bleomycin-induced cytotoxicity was not noted when the
inactive congeners of napthalenesulfonamide, W-5, or phenothiazine, chlorpromazine
sulfoxide, were used.
The potentiation of bleomycin cytotoxicity was more prominent in cell lines
naturally resistant to bleomycin. For example, Lazo et al. demonstrated a dose-
dependent enhancement of bleomycin-induced cytoxicity in human SK-OV ovarian
carcinoma cells using the calmodulin inhibitors chlorpromazine, melittin, and pimo-
zide but found no enhancement in A-253 cells, a human squamous cell carcinoma from
the head and neck region, which is more sensitive to bleomycin [28].
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In addition to noting the enhancement of cytotoxicity, these experimenters directly
examined the effects of bleomycin and calmodulin antagonists on DNA [27]. Using
alkaline elution techniques to examine DNA from the L1210 cells, the authors noted
an increased number of DNA breaks in cells treated with bleomycin in conjunction
with pimozide as compared to cells treated with bleomycin alone. DNA from cells
treated with pimozide alone did not have an increased number of breaks when
compared to DNA from untreated cells. In a cell-free system using plasmid DNA, the
authors noted no potentiation of bleomycin-induced DNA breakage with the addition
ofpimozide.
These studies suggested that the augmentation ofbleomycin-induced cytotoxicity by
calmodulin antagonists was secondary to increased damage to cellular DNA. This
increased damage could have been a direct effect of the combination or an indirect
effect mediated by inhibition of a calmodulin-mediated process of DNA repair, as
suggested by Chafouleas, Bolton, and Means [25].
Although theconcentrations ofcalmodulin antagonists required to enhance cytotox-
icity are similar to the concentrations required to inhibit calmodulin, the lack of
specificity ofcurrently utilized calmodulin antagonists makes it critical that these data
be interpreted cautiously. The strict criteria required in order to implicate calmodulin
when these drugs are used have been set forth by Hait and Lazo [22]. When followed,
these criteria will allow the interpretation that the observed potentiation ofbleomycin-
induced DNA damage is consistent with inhibition of calmodulin-sensitive DNA
repair mechanism(s) by calmodulin antagonists.
CALMODULIN ANTAGONISTS AND X-IRRADIATION
In an attempt to examine further the hypothesis that calmodulin antagonists
inhibited DNA repair processes, Lazo, Hait, et al. also treated cells with calmodulin
antagonists in combination with other agents known tocause repairable DNAdamage.
Using calmodulin antagonists in combination with X-irradiation and the chemothera-
peutic agent etoposide, the authors were unable to demonstrate cytotoxic augmenta-
tion in L1210 cells [27].
The absence of a synergistic effect between calmodulin antagonists and X-
irradiation to increase cytotoxicity and DNA damage or to decrease DNA repair was
also shown by Ridinger and his colleagues in experiments utilizing a murine mammary
carcinoma cell line. The investigators found that addition of the calmodulin inhibitor
W-13 to cell cultures prior to X-irradiation had no effect either on cell survival, the
amount ofDNA damage induced, or theabilityofthe cells torepair the X-ray-induced
DNA damage [29].
In in vivo experiments, however, George and Singh noted different effects using
X-irradiation in combination with calmodulin antagonists. When these researchers
exposed mice bearing a transplantable murine fibrosarcoma to the phenothiazine-type
drugs, promethazine, prochlorperazine, and trimeprazine, they noted no change in
tumor growth rate. When the same compounds were administered to mice prior to
X-ray treatments, however, thesedrugs potentiated thepreviously documented growth
inhibitory effects of X-irradiation [30]. Though not yet confirmed by in vitro data,
these experiments clearly suggest a possible role for phenothiazine calmodulin
antagonists in the potentiation ofX-irradiation-induced cytotoxicity, perhaps through
inhibition ofcertain DNA repair processes.
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CALMODULIN ANTAGONISTS AND HYPERTHERMIA
Increased attention has recently been focused on the potential for the use of
hyperthermia in cancer therapy since the recognition that tumor cells were more
sensitive to heat than normal cells [31]. The mechanism by which cell death is induced
by hyperthermia is not certain, but effects on DNA repair, synthesis, and replication
have been reported [32,33]. Interest has also developed in the use of hyperthermia in
conjunction with calmodulin antagonists.
Using Reuber H35 rat hepatoma cells and N3A neuroblastoma cells, Wiegant and
colleagues demonstrated significant potentiation of hyperthermic cytotoxicity when
cells were simultaneously treated with trifluoperazine [34]. Concentrations of trifluo-
perazine (5 gm and 10 ,um), which had been shown to be non-cytotoxic alone, were
found to enhance the cytotoxic effect of hyperthermia (430C for one hour). Similar
results were obtained for both the neuroblastoma and hepatoma cell lines. George and
Singh found that in vivo treatment of a transplantable murine fibrosarcoma with
non-toxicdoses ofchlorpromazine prior to treatment with hyperthermia delayed tumor
growth to a greater degree than did hyperthermia alone [35]. Again, the calmodulin
antagonists appear to play a role in inhibiting DNA repair or potentiating DNA
damage, though whether this apparent effect is due to the inhibition of a calmodulin-
dependent process or is secondary to one of the many other effects of the phenothia-
zine-type calmodulin antagonists is not yet clear.
CALMODULIN ANTAGONISTS WITH BLEOMYCIN
AND HYPERTHERMIA
Given that interactions of bleomycin and hyperthermia [36], hyperthermia and
calmodulin antagonists, and bleomycin and calmodulin antagonists have all been
shown to enhance cytotoxicity, it is not surprising that combinations ofall three agents
have been studied. Smith, Mircheva, and Bleehen, using murine EMT6 mammary
tumor cells, found that the addition ofa non-toxic dose oftrifluoperazine to bleomycin
enhanced the degree ofcytotoxicity by a factor of 1.3, while the addition ofa non-toxic
exposure to hyperthermia to bleomycin enhanced cytotoxicity by a factor of 19
[37,38]. The combination of bleomycin with trifluoperazine and hyperthermia
produced enhancement ofcytotoxicity by a factor of 1 12, a greater than additive effect.
Unfortunately, the authors did not present data showing the effect of hyperthermia
and trifluoperazine in combination without concurrent bleomycin administration.
Smith et al. examined the DNA damage caused by bleomycin, hyperthermia, and
trifluoperazine by the nucleoid sedimentation and alkaline denaturation assays [39].
The nucleoid sedimentation assay preferentially detects single-strand breaks in DNA,
whereas the alkaline denaturation assay detects both phosphodiester bond breaks in
the DNA as well as alkali-labile lesions. The alkali-labile lesions are due to the
presence ofapyrimidinic/apurinic sites (AP sites) rendering the intact DNA molecule
susceptible to alkaline denaturation. Analysis of results from the two different assays
of DNA damage showed that hyperthermia diminished the repair of bleomycin-
induced DNA damage by depressing the repair ofboth single-strand breaks (ssbs) and
AP sites, whereas trifluoperazine selectively interfered with the repair of AP sites.
Since the calmodulin antagonist, trifluoperazine, and hyperthermia appear to inhibit
the repair of DNA damage by separate mechanisms, there is a rational basis for the
synergistic enhancement ofthe cytotoxic effect ofbleomycin cited above.
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CALMODULIN ANTAGONISTS AND 254 nm UV LIGHT
The cyclobutane dimer formed by adjacent pyrimidine bases in DNA upon
absorption ofultraviolet (UV) light in the 254 nm range is a well-understood model of
DNA damage, and has been described as the "classic test lesion" for the studyofDNA
repair [40]. Research done with this experimental system assumes special importance
because the mechanism of UV-induced DNA damage and repair is so well under-
stood.
Charp and Regan examined the effects of trifluoperazine in combination with 254
nm UV light on normal-human-skin fibroblasts in culture [41]. Having prelabeled the
cells with 3H thymidine, they administered 20 Joules/meter2 (J/m2) of254 UV light to
initiate the formation of cyclobutane pyrimidine dimers. Immediately after UV
exposure, either 25 ,uM of trifluoperazine or a control solution was added, and the
percentage of pyrimidine dimers remaining was followed by two-dimensional paper
chromatographic analysis of hydrolyzed DNA from the exposed fibroblasts. After 24
hours of post-exposure incubation, the authors noted a significant difference in the
pyrimidine dimers remaining in the DNA of cells treated with trifluoperazine
compared to the control cells.
The authors tried to determine which step of the DNA repair process was affected
by trifluoperazine. Further studies with bromodeoxyuridine photolysis demonstrated
normal function ofexonuclease and polymerase activity in the presence oftrifluopera-
zine. These results led the authors to deduce that calmodulin antagonists acted upon
the incision step of the DNA repair process. Additional studies using cytosine-
arabinoside to inhibit DNA polymerase supported this conclusion.
To determine whether or not the combination of UV light with calmodulin
antagonists might be applied to the treatment ofmalignancies involving the skin, such
as cutaneous T-cell lymphoma, we studied the effect of trifluoperazine and melittin
with UV light on the L1210 murine lymphocyte leukemia. These studies failed to
demonstrate an effect of trifluoperazine and melittin on the inhibition of cellular
proliferation produced by 254 nm UV light [42]. A possible reason for this discrepancy
might be that many rodent cell lines are deficient in the repair of UV-induced
pyrimidine dimers. Mouse L cells have, however, been shown to have excision repair
mechanisms in place, although perhaps at reduced levels [43,44]. In addition, we
obtained similar results using the combination of UV exposure and trifluoperazine
with human CEM T-cell lymphoblastic leukemia cell line.
CALMODULIN ANTAGONISTS AND OTHER
CHEMOTHERAPEUTIC AGENTS
Kwok and Twentyman examined the effects of a number of cytotoxic chemothera-
peutic agents in combination with trifluoperazine [45]. They used small spheroids of
murine EMT6/Ca/VJAC mammary tumor cells treated with bleomycin, CCNU,
nitrogen mustard, and X-irradiation followed by exposure to non-toxic concentrations
oftrifluoperazine. No difference was noted in the surviving fraction ofcells exposed to
trifluoperazine when that was compared to the surviving fraction ofcells exposed to the
cytotoxic agent alone.
Darkin and his colleagues found that DNA isolated from PY815 cell nuclei was
damaged after treatment with the DNA intercalating agent m-AMSA [46]. The DNA
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was resealed when the nuclei underwent subsequent incubation in drug-free medium.
The degree of repair was, however, significantly imhibited when incubation took place
in the presence of chlorpromazine.
Interactions between doxorubicin and related anthracyclines with calmodulin
antagonists have been explored by Ganapathi and his associates [47,48]. Much of their
work has involved the use of a doxorubicin-resistant P388/DOX murine leukemia line,
where they have demonstrated up to a 100-fold increase in anthracycline-induced
cytotoxicity with the use of trifluoperazine. The mechanisms underlying the resistance
of these cells to doxorubicin and other compounds are unclear (for a recent review, see
[49]). Cytotoxic enhancement was also noted in experiments with the non-resistant
P388/S cell line. These results were dose-dependent and were noted with both
trifluoperazine and chlorpromazine at concentrations appropriate to the potency of the
two compounds as calmodulin antagonists [44].
In further experiments with the non-resistant P388/S cell line, Ganapathi and his
associates noted that calmodulin antagonists preferentially enhanced the cytotoxicity
of strong DNA binding agents, including the chemotherapeutic agents dactinomycin
and AMSA, in addition to the anthracyclines doxorubicin and daunorubicin [50]. In
contrast, they did not note enhancement of cytotoxicity when weakly DNA-binding
anthracycline analogs were used. The mechanism of cytotoxic enhancement in the
sensitive P388/S cell line is less well understood than in the resistant phenotype, where
attention has been focused on differences in cellular uptake and retention of the
anthracyclines [44,45]. The existence of cytotoxic enhancement of strong DNA
binding agents from a variety of different structural classes by calmodulin antagonists
again suggests, however, that calmodulin may be involved in DNA damage and
repair.
The studies of agents that induce DNA damage with calmodulin antagonists are
summarized in Table 1. Several explanations are possible for the inconsistent results
obtained. In many of these experiments assessing cytotoxicity, several different assay
systems are used to determine dose-response effects, such as cell count by coulter
counter to quantitate cell growth inhibition, the clonogenic assay which looks at the
number ofcolonies formed to quantitate cell survival, or growth delay as used in in vivo
tumor systems, each having different sensitivities and specificities [51]. Also, individ-
ual cell lines display a variety of sensitivities to agents used, as demonstrated by Lazo
and associates in their studies using bleomycin in conjunction with calmodulin
antagonists [28].
Other difficulties arise in definitively ascribing effects obtained with calmodulin
antagonists to the inhibition ofcalmodulin. Known calmodulin antagonists suffer from
a lack of specificity and are known to exert effects on cellular components such as
membranes and hormone receptors, in particular the phorbol ester receptor believed to
be the phospholipid, Ca++ stimulated protein kinase (C-kinase), which are not directly
linked to their effects as calmodulin antagonists. This action complicates their use as
tools for the elucidation of calmodulin-dependent processes [18]. Interpretation of
experimental data is also complicated by the lack of precise techniques for the assay of
DNA repair inhibition, necessitating the use of biological end-points in the place of
more specific assays [52]. Future studies using the newly synthesized calmodulin
antagonist, CGS-9343B, a drug shown to inhibit calmodulin-sensitive enzymes out of
proportion to its effect on protein kinase C and to its effect on dopamine receptors,
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TABLE 1
Summary of Studies Using Calmodulin Antagonists in Combination with Physical and Chemical
Agents Which Damage DNA
DNA-Damaging Experimental Calmodulin











































































































Abbreviations: TFP, trifluoperazine; CPZ, chlorpromazine; PIM, pimozide; Mel, melittin; Mas, mastopo-
ran; PMZ, promethazine; PPZ, prochlorperazine; TPZ, trimeprazine
should help to elucidate the role of calmodulin [54]. Furthermore, studies using
isolated nuclei and purified nuclear enzymes should help to define precisely the
proposed calmodulin-dependent processes.
In spite of these difficulties in interpreting experimental data, there is reason to be
optimistic about the future role of calmodulin antagonists in anti-neoplastic therapy.
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relatively well tolerated and non-toxic in their clinical use for psychiatric disorders.
Some have already begun to be used in combination with other agents in clinical trials.
Based on the observed in vitro potentiation of bleomycin-induced cytotoxicity by
calmodulin antagonists, a phase I-IT study using trifluoperazine in combination with
bleomycin was conducted. Patients with a variety of malignancies, including mycosis
fungoides and gynecologic malignancies, were enrolled in the study. Although neuro-
psychiatric side effects and other toxicities were noted, 4 of 19 patients had measurable
responses to the experimental regimen, warranting further clinical evaluation [53].
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